{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:40:26Z","timestamp":1785886826249,"version":"3.56.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T00:00:00Z","timestamp":1650758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T00:00:00Z","timestamp":1650758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To examine the effectiveness of Janus-kinase inhibitors (JAKis) or abatacept (ABA) in patients with rheumatoid arthritis-interstitial lung disease (RA-ILD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with RA-ILD receiving JAKis or ABA were retrospectively evaluated at baseline and after 18\u00a0months of treatment. A computer-aided method (CaM) was used to assess the extent of high-resolution computed tomography (HRCT) fibrosis percentage. According to HRCT fibrosis changes, patients were classified as \u201cworsened\u201d (progression of\u00a015%\u00a0or more), \u201cstable\u201d (changes within 15%) or \u201cimproved\u201d (reduction of\u00a015%\u00a0or more). Correlations between RA characteristics and JAKis or ABA responses were studied using a multivariate regression model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seventy-five patients (69.3% women) were evaluated, 31 received a\u00a0JAKi while 44 received ABA. In the JAKis group, five patients (16.1%) showed RA-ILD progression, 20 patients (64.5%) were considered stable, and six patients (19.4%) demonstrated RA-ILD improvement. In the ABA group, five patients (11.3%) showed RA-ILD progression, 32 patients (72.7%) were stable, and seven patients (16.0%) demonstrated RA-ILD improvement. In both groups, the percentage of current smokers was different between those classified as \"worsened\" and those classified as \"improved\/stable\" (<jats:italic>p<\/jats:italic>\u2009=\u20090.01). In multivariate regression analysis, current smoking habit (<jats:italic>p<\/jats:italic>\u2009=\u20090.0051) and concomitant methotrexate treatment (<jats:italic>p<\/jats:italic>\u2009=\u20090.0078) were the two variables related to RA-ILD progression in ABA-treated patients, whereas in JAKis-treated patients, the only RA-ILD progression-related variable was disease duration of RA (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Treatment with JAKis or ABA was related to stability or improvement of RA-ILD in 83.9% and 88.6% of patients, respectively. RA duration is the only variable associated with worsening RA-ILD in JAKis-treated patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10787-022-00936-w","type":"journal-article","created":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T18:02:35Z","timestamp":1650823355000},"page":"705-712","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4764-7197","authenticated-orcid":false,"given":"Marika","family":"Tardella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0906-4647","authenticated-orcid":false,"given":"Marco","family":"Di Carlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6562-180X","authenticated-orcid":false,"given":"Marina","family":"Carotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0510-0970","authenticated-orcid":false,"given":"Luca","family":"Ceccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5264-652X","authenticated-orcid":false,"given":"Andrea","family":"Giovagnoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3794-6831","authenticated-orcid":false,"given":"Fausto","family":"Salaffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,24]]},"reference":[{"key":"936_CR1","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ et al (2010) 2010 Rheumatoid arthritis classification criteria: an american college of rheumatology\/European league against rheumatism collaborative initiative. Arthritis Rheum 62:2569\u20132581","journal-title":"Arthritis Rheum"},{"key":"936_CR2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00296-013-2845-6","volume":"34","author":"A Ariani","year":"2014","unstructured":"Ariani A, Carotti M, Gutierrez M et al (2014) Utility of an open-source DICOM viewer software (OsiriX) to assess pulmonary fibrosis in systemic sclerosis: preliminary results. Rheumatol Int 34:511\u2013516","journal-title":"Rheumatol Int"},{"key":"936_CR3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","volume":"381","author":"Z Chen","year":"2019","unstructured":"Chen Z, Wang X, Ye S (2019) Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. New Engl J Med 381:291\u2013293","journal-title":"New Engl J Med"},{"key":"936_CR4","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.1097\/RHU.0000000000001552","volume":"27","author":"G Citera","year":"2021","unstructured":"Citera G, Mysler E, Madariaga H et al (2021) Incidence rates of interstitial lung disease events in tofacitinib-treated rheumatoid arthritis patients: post hoc analysis from 21 clinical trials. J Clin Rheumaol 27:e482\u2013e490","journal-title":"J Clin Rheumaol"},{"key":"936_CR5","doi-asserted-by":"crossref","first-page":"106748","DOI":"10.1016\/j.intimp.2020.106748","volume":"86","author":"M d\u2019Alessandro","year":"2020","unstructured":"d\u2019Alessandro M, Perillo F, Metella Refini R et al (2020) Efficacy of baricitinib in treating rheumatoid arthritis: modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting. Int Immunopharmacol 86:106748","journal-title":"Int Immunopharmacol"},{"key":"936_CR6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/ard.61.6.517","volume":"61","author":"JK Dawson","year":"2002","unstructured":"Dawson JK, Fewins HE, Desmond J et al (2002) Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis 61:517\u2013521","journal-title":"Ann Rheum Dis"},{"key":"936_CR7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/BOR.0000000000000703","volume":"32","author":"BR England","year":"2020","unstructured":"England BR, Hershberger D (2020) Management issues in rheumatoid arthritis-associated interstitial lung disease. Curr Opin Rheumatol 32:255\u2013263","journal-title":"Curr Opin Rheumatol"},{"key":"936_CR8","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.55563\/clinexprheumatol\/h9tc57","volume":"39","author":"MS Fazeli","year":"2021","unstructured":"Fazeli MS, Khaychuk V, Wittstock K et al (2021) Rheumatoid arthritis-associated interstitial lung disease: epidemiology, risk\/prognostic factors, and treatment landscape. Clin Exp Rheumatol 39:1108\u20131118","journal-title":"Clin Exp Rheumatol"},{"key":"936_CR9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S et al (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet 390:457\u2013468","journal-title":"Lancet"},{"key":"936_CR10","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR et al (2021) 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (hoboken) 73:924\u2013939","journal-title":"Arthritis Care Res (hoboken)"},{"key":"936_CR11","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1093\/rheumatology\/ker289","volume":"50","author":"AV Hadjinicolaou","year":"2011","unstructured":"Hadjinicolaou AV, Nisar MK, Bhagat S et al (2011) Non-infectious pulmonary complications of newer biological agents for rheumatic diseases-a systematic literature review. Rheumatol (oxford) 50:2297\u20132305","journal-title":"Rheumatol (oxford)"},{"key":"936_CR12","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","volume":"58","author":"CR Holroyd","year":"2019","unstructured":"Holroyd CR, Seth R, Bukhari M et al (2019) The british society for rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatol (oxford) 58:e3\u2013e42","journal-title":"Rheumatol (oxford)"},{"key":"936_CR13","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/rheumatology\/keaa117","volume":"59","author":"JK Khoo","year":"2020","unstructured":"Khoo JK, Barnes H, Key S et al (2020) Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis. Rheumatol (oxford) 59:2217\u20132225","journal-title":"Rheumatol (oxford)"},{"key":"936_CR14","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/1756-185X.12822","volume":"19","author":"YH Lee","year":"2016","unstructured":"Lee YH, Bae SC (2016) Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a bayesian network meta-analysis of randomized controlled trials. Int J Rheum Dis 19:1103\u20131111","journal-title":"Int J Rheum Dis"},{"key":"936_CR15","doi-asserted-by":"crossref","first-page":"114103","DOI":"10.1016\/j.bcp.2020.114103","volume":"178","author":"A Lescoat","year":"2020","unstructured":"Lescoat A, Lelong M, Jeljeli M et al (2020) Combined anti-fibrotic and anti-inflammatory properties of jak-inhibitors on macrophages in vitro and in vivo: perspectives for scleroderma-associated interstitial lung disease. Biochem Pharmacol 178:114103","journal-title":"Biochem Pharmacol"},{"key":"936_CR16","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/imj.14670","volume":"50","author":"A Manfredi","year":"2020","unstructured":"Manfredi A, Cassone G, Furini F et al (2020) Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. Intern Med J 50:1085\u20131090","journal-title":"Intern Med J"},{"key":"936_CR600","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1093\/rheumatology\/keaa503","volume":"59","author":"J Narv\u00e1ez","year":"2020","unstructured":"Narv\u00e1ez J, Vicens-Zygmunt V, Alegre JJ et al (2020) Nintedanib for the treatment of refractory progressive rheumatoid arthritis-related interstitial lung disease: a real-life case series. Rheumatology (Oxford) 59:3983\u20133986","journal-title":"Rheumatology (Oxford)"},{"key":"936_CR17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","volume":"80","author":"P Nash","year":"2021","unstructured":"Nash P, Kerschbaumer A, D\u00f6rner T et al (2021) Points to consider for the treatment of immune-mediated inflammatory diseases with janus kinase inhibitors: a consensus statement. Ann Rheum Dis 80:71\u201387","journal-title":"Ann Rheum Dis"},{"key":"936_CR18","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1093\/rheumatology\/keaa323","volume":"59","author":"M Pineton de Chambrun","year":"2020","unstructured":"Pineton de Chambrun M, Hervier B, Chauveau S et al (2020) Tofacitinib in antisynthetase syndrome-related rapidly progressive interstitial lung disease. Rheumatol (oxford) 59:e142\u2013e143","journal-title":"Rheumatol (oxford)"},{"issue":"4","key":"936_CR19","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3899\/jrheum.171315","volume":"46","author":"K Raimundo","year":"2019","unstructured":"Raimundo K, Solomon JJ, Olson AL et al (2019) Rheumatoid arthritis-interstitial lung disease in the united states: prevalence, incidence, and healthcare costs and mortality. J Rheumatol 46(4):360\u2013369","journal-title":"J Rheumatol"},{"key":"936_CR20","doi-asserted-by":"crossref","first-page":"L998","DOI":"10.1152\/ajplung.00304.2017","volume":"314","author":"EF Redente","year":"2018","unstructured":"Redente EF, Aguilar MA, Black BP et al (2018) Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease. Am J Physiol Lung Cell Mol Physiol 314:L998\u2013L1009","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"936_CR21","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s10067-017-3707-5","volume":"36","author":"J Rojas-Serrano","year":"2017","unstructured":"Rojas-Serrano J, Herrera-Bringas D, P\u00e9rez-Rom\u00e1n DI et al (2017) Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis. Clin Rheumatol 36:1493\u20131500","journal-title":"Clin Rheumatol"},{"key":"936_CR22","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.semarthrit.2020.03.007","volume":"50","author":"F Romero-Bueno","year":"2020","unstructured":"Romero-Bueno F, Diaz Del Campo P, Trallero-Aragu\u00e1s E et al (2020) Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum 50:776\u2013790","journal-title":"Semin Arthritis Rheum"},{"key":"936_CR23","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","volume":"43","author":"C Roubille","year":"2014","unstructured":"Roubille C, Haraoui B (2014) Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 43:613\u2013626","journal-title":"Semin Arthritis Rheum"},{"key":"936_CR24","first-page":"819","volume":"23","author":"F Salaffi","year":"2005","unstructured":"Salaffi F, De Angelis R, Grassi W (2005) Prevalence of musculoskeletal conditions in an italian population sample: results of a regional community-based Study I. MAPP Study Clin Exp Rheumatol 23:819\u2013828","journal-title":"MAPP Study Clin Exp Rheumatol"},{"key":"936_CR25","doi-asserted-by":"crossref","first-page":"e17088","DOI":"10.1097\/MD.0000000000017088","volume":"98","author":"F Salaffi","year":"2019","unstructured":"Salaffi F, Carotti M, Di Carlo M et al (2019) High-Resolution Computed tomography of the lung in patients with rheumatoid arthritis: prevalence of interstitial lung disease involvement and determinants of abnormalities. Med (baltim) 98:e17088","journal-title":"Med (baltim)"},{"key":"936_CR26","doi-asserted-by":"crossref","first-page":"e22433","DOI":"10.1097\/MD.0000000000022433","volume":"99","author":"F Salaffi","year":"2020","unstructured":"Salaffi F, Carotti M, Tardella M et al (2020a) The role of a chest computed tomography severity score in coronavirus disease 2019 pneumonia. Med (baltim) 99:e22433","journal-title":"Med (baltim)"},{"key":"936_CR27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejim.2020.02.009","volume":"76","author":"F Salaffi","year":"2020","unstructured":"Salaffi F, Carotti M, Tardella M et al (2020b) Computed tomography assessment of evolution of interstitial lung disease in systemic sclerosis: comparison of two scoring systems. Eur J Intern Med 76:71\u201375","journal-title":"Eur J Intern Med"},{"key":"936_CR28","first-page":"137","volume":"26","author":"LM Saldarriaga-Rivera","year":"2019","unstructured":"Saldarriaga-Rivera LM, L\u00f3pez-Villegas VJ (2019) Janus kinase inhibitors as a therapeutic option in rheumatoid arthritis and associated interstitial lung disease. report of four cases. Rev Colomb Reumatol 26:137\u2013139","journal-title":"Rev Colomb Reumatol"},{"key":"936_CR29","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s40744-021-00332-w","volume":"8","author":"C Salvarani","year":"2021","unstructured":"Salvarani C, Sebastiani M, Dieude P et al (2021) Baricitinib and the risk of incident interstitial lung disease: a descriptive clinical case report from clinical trials. Rheumatol Ther 8:1435\u20131441","journal-title":"Rheumatol Ther"},{"key":"936_CR30","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13075-019-1963-2","volume":"21","author":"SJ SendoS","year":"2019","unstructured":"SendoS SJ, Yamada H et al (2019) Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice. Arthritis Res Ther 21:184","journal-title":"Arthritis Res Ther"},{"key":"936_CR602","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1007\/s12325-019-01086-2","volume":"36","author":"JJ Solomon","year":"2019","unstructured":"Solomon JJ, Danoff SK, Goldberg HJ et al (2019) The Design and rationale of the trail1 trial: a randomized double-blind phase 2 clinical trial of pirfenidone in rheumatoid arthritis-associated interstitial lung disease. Adv Ther 36:3279\u20133287","journal-title":"Adv Ther"},{"key":"936_CR31","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jbspin.2007.10.009","volume":"75","author":"M Soubrier","year":"2008","unstructured":"Soubrier M, Jeannin G, Kemeny JL et al (2008) Organizing pneumonia after rituximab therapy: two cases. Joint Bone Spine 75:362\u2013365","journal-title":"Joint Bone Spine"},{"key":"936_CR32","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/art.40574","volume":"70","author":"P Spagnolo","year":"2018","unstructured":"Spagnolo P, Lee JS, Sverzellati N et al (2018) The Lung in rheumatoid arthritis: focus on interstitial lung disease. Arthritis Rheumatol 70:1544\u20131552","journal-title":"Arthritis Rheumatol"},{"key":"936_CR33","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1007\/s10067-021-05854-w","volume":"40","author":"M Tardella","year":"2021","unstructured":"Tardella M, Di Carlo M, Carotti M et al (2021) Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression. Clin Rheumatol 40:4861\u20134867","journal-title":"Clin Rheumatol"},{"key":"936_CR34","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM et al (2013) An Official american thoracic society\/European respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188:733\u2013748","journal-title":"Am J Respir Crit Care Med"},{"key":"936_CR501","doi-asserted-by":"crossref","first-page":"6390749","DOI":"10.1155\/2020\/6390749","volume":"2020","author":"C Vacchi","year":"2020","unstructured":"Vacchi C, Manfredi A, Cassone G et al (2020) Combination therapy with nintedanib and sarilumab for the management of rheumatoid arthritis related interstitial lung disease. Case Rep Med 2020:6390749","journal-title":"Case Rep Med"},{"key":"936_CR500","doi-asserted-by":"crossref","first-page":"6652845","DOI":"10.1155\/2021\/6652845","volume":"2021","author":"C Vacchi","year":"2021","unstructured":"Vacchi C, Manfredi A, Cassone G et al (2021) To facitinib for the treatment of severe interstitial lung disease related to rheumatoid arthritis. Case Rep Med 2021:6652845","journal-title":"Case Rep Med"},{"key":"936_CR35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41584-020-00567-x","volume":"17","author":"AU Wells","year":"2021","unstructured":"Wells AU (2021) New insights into the treatment of CTD-ILD. Nat Rev Rheumatol 17:79\u201380","journal-title":"Nat Rev Rheumatol"},{"key":"936_CR502","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","volume":"8","author":"AU Wells","year":"2020","unstructured":"Wells AU, Flaherty KR, Brown KK et al (2020) Nintedanib in patients with progressive fibrosing interstitial lung diseases\u2014subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 8:453\u2013460","journal-title":"Lancet Respir Med"},{"key":"936_CR36","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jbspin.2013.03.009","volume":"80","author":"D Wendling","year":"2013","unstructured":"Wendling D, Vidon C, Godfrin-Valnet M et al (2013) Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis. Joint Bone Spine 80:670\u2013671","journal-title":"Joint Bone Spine"},{"key":"936_CR601","volume":"74","author":"C Wu","year":"2019","unstructured":"Wu C, Lin H, Zhang X (2019) Inhibitory effects of pirfenidone on fibroblast to myofibroblast transition in rheumatoid arthritis-associated interstitial lung disease via the downregulation of activating transcription factor 3 (ATF3). Int Immunopharmacol 74:105700","journal-title":"Int Immunopharmacol"},{"key":"936_CR37","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.39971","volume":"69","author":"JA Zamora-Legoff","year":"2017","unstructured":"Zamora-Legoff JA, Krause ML, Crowson CS et al (2017) Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol 69:542\u2013549","journal-title":"Arthritis Rheumatol"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-022-00936-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-022-00936-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-022-00936-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T10:43:13Z","timestamp":1660560193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-022-00936-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,24]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["936"],"URL":"https:\/\/doi.org\/10.1007\/s10787-022-00936-w","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,24]]},"assertion":[{"value":"31 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No competing interests to be declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The local Ethics Committee (Comitato Unico Regionale-ASUR Marche) approved the protocol. The study was conducted in accordance with the Helsinki Declaration in its fifth edition (2000).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients signed an informed consent for inclusion of personal records in the local database and for use to scientific research purposes.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}